Avidity Biosciences Inc (RNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 958.74 is considered Overvalued compared with the five-year average of -7.28. The fair price of Avidity Biosciences Inc (RNA) is between 0.78 to 6.94 according to relative valuation method. Compared to the current price of 15.43 USD , Avidity Biosciences Inc By Overvalued By 122.31%.

Relative Value

Fair Zone

0.78-6.94

Current Price：15.43

122.31%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Avidity Biosciences Inc (RNA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Avidity Biosciences Inc (RNA) has a current Price-to-Book (P/B) ratio of 5.61. Compared to its 3-year average P/B ratio of 2.83, the current P/B ratio is approximately 98.18% higher. Relative to its 5-year average P/B ratio of 2.73, the current P/B ratio is about 105.43% higher. Avidity Biosciences Inc (RNA) has a Forward Free Cash Flow (FCF) yield of approximately -5.45%. Compared to its 3-year average FCF yield of -12.65%, the current FCF yield is approximately -56.92% lower. Relative to its 5-year average FCF yield of -11.80%, the current FCF yield is about -53.82% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RNA competitors is 193.51, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA.O) exhibits a P/S ratio of 958.74, which is 395.44% above the industry average. Given its robust revenue growth of -71.07%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RNA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RNA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RNA currently overvalued or undervalued?

Avidity Biosciences Inc (RNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 958.74 is considered Overvalued compared with the five-year average of -7.28. The fair price of Avidity Biosciences Inc (RNA) is between 0.78 to 6.94 according to relative valuation method. Compared to the current price of 15.43 USD, Avidity Biosciences Inc is Overvalued By 122.31%.

What is Avidity Biosciences Inc (RNA) fair value?

RNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Avidity Biosciences Inc (RNA) is between 0.78 to 6.94 according to relative valuation method.

How does RNA's valuation metrics compare to the industry average?

The average P/S ratio for RNA's competitors is 193.51, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA) exhibits a P/S ratio of 958.74, which is 395.44% above the industry average. Given its robust revenue growth of -71.07%, this premium appears unsustainable.

What is the current P/B ratio for Avidity Biosciences Inc (RNA) as of Mar 03 2026?

As of Mar 03 2026, Avidity Biosciences Inc (RNA) has a P/B ratio of 5.61. This indicates that the market values RNA at 5.61 times its book value.

What is the current FCF Yield for Avidity Biosciences Inc (RNA) as of Mar 03 2026?

As of Mar 03 2026, Avidity Biosciences Inc (RNA) has a FCF Yield of -5.45%. This means that for every dollar of Avidity Biosciences Inc's market capitalization, the company generates -5.45 cents in free cash flow.

What is the current Forward P/E ratio for Avidity Biosciences Inc (RNA) as of Mar 03 2026?

As of Mar 03 2026, Avidity Biosciences Inc (RNA) has a Forward P/E ratio of -13.80. This means the market is willing to pay $-13.80 for every dollar of Avidity Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Avidity Biosciences Inc (RNA) as of Mar 03 2026?

As of Mar 03 2026, Avidity Biosciences Inc (RNA) has a Forward P/S ratio of 958.74. This means the market is valuing RNA at $958.74 for every dollar of expected revenue over the next 12 months.

RNA Valuation